Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intravenous Allopurinol in Heart Failure

This study has been completed.
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Robert G. Weiss, Johns Hopkins University Identifier:
First received: September 12, 2005
Last updated: January 6, 2016
Last verified: January 2016
This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.

Condition Intervention Phase
Congestive Heart Failure
Drug: Allopurinol
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Xanthine Oxidase Inhibition on Mechano-Energetic Coupling in Heart Failure

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion [ Time Frame: Onset of imaging acquisition. ]
    Magnetic resonance spectroscopy (MRS) Measurement of Myocardial CK Flux Pre Intravenous Allopurinol Infusion

  • Myocardial CK Flux Post Intravenous Allopurinol Infusion. [ Time Frame: acute (within 15 minutes of single infusion) ]
    The mean rate of adenosine triphosphate (ATP) flux through the creatine kinase reaction in the heart.

Secondary Outcome Measures:
  • Cardiac PCr/ATP Pre Intravenous Infusion [ Time Frame: Onset of image acquisition. ]
    The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.

  • Cardiac PCr/ATP Post Intravenous Infusion [ Time Frame: acute (within 15 minutes of single infusion) ]
    The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.

Enrollment: 18
Study Start Date: November 2004
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Allopurinol
One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
Drug: Allopurinol
intravenous infusion of allopurinol (300mg)
Other Name: Aloprim
Placebo Comparator: Placebo
One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.
Drug: Placebo
intravenous infusion of 50 ml dose of 5% dextrose
Other Name: 5% Dextrose

Detailed Description:

Xanthine oxidase have been reported to improve mechano-energetic coupling in failing hearts. The investigators developed a means to directly measure creatine kinase flux, the major energy reserve of the heart, in the human heart exploiting new magnetic resonance technologies.

The investigators propose to study 10 healthy subjects and up to 25 with heart failure (dilated cardiomyopathy) before and after a single 300mg IV infusion of allopurinol.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age > 18 years
  2. The patient is willing and able to provide informed consent
  3. Clinical diagnosis of chronic heart failure
  4. Ejection fraction (EF) < 40% by echocardiography, nuclear multigated acquisition (MUGA) or cath ventriculography
  5. No significant coronary disease at cardiac catheterization
  6. New York Heart Association (NYHA) Class I-IV symptoms
  7. Clinical stabilization for two weeks if following recent congestive heart failure (CHF) decompensation.

Exclusion Criteria:

  1. Metallic implant prohibiting magnetic resonance (MR) evaluation
  2. Inability to lie flat for MR study
  3. Administration of additional investigational drugs
  4. Calculated creatinine clearance < 50 mL/min
  5. Allergy to allopurinol
  6. Current gout flare
  7. Currently taking oral allopurinol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00181155

United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Johns Hopkins University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Robert G Weiss, MD Johns Hopkins University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Robert G. Weiss, Professor of Medicine and Radiology, Johns Hopkins University Identifier: NCT00181155     History of Changes
Other Study ID Numbers: IRB: 04-10-12-06
5R01HL061912-14 ( US NIH Grant/Contract Award Number )
Study First Received: September 12, 2005
Results First Received: November 11, 2015
Last Updated: January 6, 2016

Keywords provided by Johns Hopkins University:
congestive heart failure
Adenosine triphosphate (ATP)

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Protective Agents
Physiological Effects of Drugs processed this record on May 25, 2017